Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ristocetin induces platelet aggregation: a morphological demonstration.

G Escolar1, J Monteagudo, N Villamor

  • 1Hospital Clínic i Provincial, Facultad de Medicina, Universidad de Barcelona, Spain.

British Journal of Haematology
|July 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A freeze-dried platelet-derived hemostatic agent improves hemostasis in patients with severe thrombocytopenia before and after standard platelet transfusion: Studies ex vivo in the total thrombus-formation analysis system 01.

Transfusion·2026
Same author

Diagnostic challenges in von Willebrand disease. Report of two cases with emphasis on multimeric and molecular analysis.

Platelets·2020
Same author

Towards the understanding of the UV light, riboflavin and additive solution contributions to the in vitro lesions observed in Mirasol®-treated platelets.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2019
Same author

Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.

Drugs of today (Barcelona, Spain : 1998)·2018
Same author

Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: comment.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.

Drugs of today (Barcelona, Spain : 1998)·2017

Ristocetin-induced platelet aggregation (RIPA) in citrated platelet-rich plasma (c-PRP) reveals ultrastructural changes and serotonin release. RIPA in c-PRP assesses platelet function beyond GPIb-vWF interaction, including GPIIb/IIIa complex assembly and fibrinogen binding.

Area of Science:

  • Hematology
  • Cell Biology
  • Biochemistry

Background:

  • Platelet aggregation is crucial for hemostasis.
  • Ristocetin-induced platelet aggregation (RIPA) is a standard diagnostic test.
  • The precise mechanisms underlying RIPA in various conditions require further elucidation.

Purpose of the Study:

  • To investigate the ultrastructural changes in human platelets induced by ristocetin.
  • To measure serotonin release during ristocetin-induced platelet aggregation.
  • To analyze modifications in aggregation tests using apyrase, a monoclonal antibody (Mab) to GPIIb/IIIa, and EDTA.

Main Methods:

  • Transmission electron microscopy with a tannic acid procedure.
  • Serotonin release assays.
  • Platelet aggregation studies in platelet-rich plasma (PRP) under various conditions (citrated, EDTA-treated).

Related Experiment Videos

Main Results:

  • Ristocetin induced precipitation of adhesive proteins on the platelet membrane, forming electron-dense deposits.
  • Platelet activation, shape change, aggregation, and partial content release were observed during stirring in aggregometer cuvettes.
  • A Mab to GPIIb/IIIa affected aggregation extent and rate in c-PRP, while apyrase affected extent only.
  • Neither Mab nor apyrase altered RIPA in EDTA-treated PRP.

Conclusions:

  • RIPA in c-PRP assesses platelet function beyond the GPIb-von Willebrand factor interaction.
  • RIPA may also evaluate GPIIb/IIIa complex assembly and fibrinogen interaction.
  • The release reaction might also be assessed through RIPA in c-PRP.